(MedPage Today) — Investigational efimosfermin alfa was safe and well tolerated among patients with phenotypic metabolic dysfunction-associated steatohepatitis (MASH), a randomized phase IIa trial showed.
Among 65 participants treated with efimosfermin…
Source link : https://www.medpagetoday.com/gastroenterology/generalhepatology/116041
Author :
Publish date : 2025-06-12 18:13:00
Copyright for syndicated content belongs to the linked Source.
